Literature DB >> 22023061

Botulinum toxin injections into the detrusor.

Jens Wöllner1, Thomas M Kessler.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22023061     DOI： 10.1111/j.1464-410X.2011.10675.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  5 in total

1.  [Neurogenic detrusor overactivity and onabotulinumtoxin A (Botox®) : Is perioperative antbiotic prophylaxis unnecessary?]

Authors:  A Kaufmann
Journal:  Urologe A       Date:  2017-02       Impact factor: 0.639

2.  Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction.

Authors:  Stephanie C Knüpfer; Martina D Liechti; Livio Mordasini; Dominik Abt; Daniel S Engeler; Jens Wöllner; Jürgen Pannek; Bernhard Kiss; Fiona C Burkhard; Marc P Schneider; Elena Miramontes; Alfons G Kessels; Lucas M Bachmann; Thomas M Kessler
Journal:  BMC Urol       Date:  2014-08-13       Impact factor: 2.264

3.  Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity.

Authors:  Lorenz Leitner; Matthias Walter; Patrick Freund; Ulrich Mehnert; Lars Michels; Spyros Kollias; Thomas M Kessler
Journal:  BMC Urol       Date:  2014-08-18       Impact factor: 2.264

4.  Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity.

Authors:  Lorenz Leitner; Ulla Sammer; Matthias Walter; Stephanie C Knüpfer; Marc P Schneider; Burkhardt Seifert; Jure Tornic; Ulrich Mehnert; Thomas M Kessler
Journal:  Sci Rep       Date:  2016-09-12       Impact factor: 4.379

5.  TASCI-transcutaneous tibial nerve stimulation in patients with acute spinal cord injury to prevent neurogenic detrusor overactivity: protocol for a nationwide, randomised, sham-controlled, double-blind clinical trial.

Authors:  Veronika Birkhäuser; Martina D Liechti; Collene E Anderson; Lucas M Bachmann; Sarah Baumann; Michael Baumberger; Lori A Birder; Sander M Botter; Silvan Büeler; Célia D Cruz; Gergely David; Patrick Freund; Susanne Friedl; Oliver Gross; Margret Hund-Georgiadis; Knut Husmann; Xavier Jordan; Miriam Koschorke; Lorenz Leitner; Eugenia Luca; Ulrich Mehnert; Sandra Möhr; Freschta Mohammadzada; Katia Monastyrskaya; Nikolai Pfender; Daniel Pohl; Helen Sadri; Andrea M Sartori; Martin Schubert; Kai Sprengel; Stephanie A Stalder; Jivko Stoyanov; Cornelia Stress; Aurora Tatu; Cécile Tawadros; Stéphanie van der Lely; Jens Wöllner; Veronika Zubler; Armin Curt; Jürgen Pannek; Martin W G Brinkhof; Thomas M Kessler
Journal:  BMJ Open       Date:  2020-08-13       Impact factor: 2.692
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.